Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioDelivery Sciences' Prochlorperazine Oral Buccal Tablet Is Bucked Off Course

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA "not approvable" letter for Emezine is due to the pharmacokinetic profile of its oral buccal tablet formulation.

You may also be interested in...



BioDelivery Sciences Planning Two Emezine PK Studies To Satisfy FDA Concerns

The company believes that the studies of the anti-emetic will take six to nine months to complete.

India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs

Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.

Topics

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel